Custom Formulation & Conjugation Solutions
Creative Biolabs offers comprehensive custom formulation and conjugation services that transform nucleic acid therapeutics into clinically viable delivery systems. Our advanced platform combines cutting-edge nanoparticle technologies with sophisticated bioconjugation strategies, enabling targeted and efficient delivery of RNA and DNA-based therapeutics. From lipid nanoparticle formulations to antibody-oligonucleotide conjugates, our services address the critical challenges of nucleic acid delivery including stability, targeting, and cellular uptake, accelerating the translation of your therapeutic concepts into effective treatments.
Our Services
Harness the proven power of lipid nanoparticle technology for your nucleic acid delivery needs. Our LNP formulation platform, validated through successful COVID-19 mRNA vaccines, offers versatile encapsulation of diverse nucleic acid cargoes including mRNA, siRNA, ASOs, and CRISPR components. Our four-component LNP system utilizes carefully optimized ionizable lipids for efficient encapsulation (>90%), PEG-lipids for stability and circulation, phospholipids for structural support and endosomal escape, and cholesterol for membrane integrity. We employ state-of-the-art microfluidic mixing technology for scalable, reproducible production from research to clinical scales. Our LNPs demonstrate high in vitro and in vivo delivery efficiency with low toxicity, supported by comprehensive characterization including DLS, zeta potential, and encapsulation efficiency measurements. Applications span from mRNA vaccines and gene therapy to protein replacement and CAR-T cell engineering, with options for tissue-specific targeting through ligand conjugation.
Antibody-siRNA Conjugates (ARCs)
Unlock the precision of antibody targeting combined with the therapeutic potential of RNA interference through our ARC development services. Our platform offers multiple conjugation strategies tailored to your specific needs: non-covalent assembly through electrostatic interactions for rapid screening, site-specific thiol-maleimide chemistry for stable conjugation, cell-penetrating peptide bridges for enhanced cellular uptake, and Fab-based conjugates for improved tissue penetration. Each approach is optimized for your target tissue and therapeutic application, from cancer treatment to muscle disorders. Our ARCs demonstrate enhanced circulation time, specific cellular targeting, and improved gene silencing efficiency compared to unconjugated siRNA. With proven success in delivering therapeutic siRNAs to solid tumors, muscle cells, and other challenging targets, our ARC technology provides a versatile solution for targeted gene therapy applications.
Antibody-Oligo Conjugates (AOCs)
Expand your therapeutic possibilities with our comprehensive AOC platform that extends beyond siRNA to include ASOs and other oligonucleotide modalities. Our four distinct conjugation methods provide flexibility for diverse applications: ionic interaction-based coupling for screening multiple oligonucleotides, avidin-biotin bridging for stable in vivo performance, direct conjugation to lysine or cysteine residues for minimal structural impact, and hybridization-based assembly for diagnostic applications. Each AOC is characterized by high coupling efficiency (>90%), exceptional purity verified by SEC-HPLC, and maintained antibody functionality. Our streamlined production process achieves yields up to 80% while maintaining strict quality standards. Applications range from therapeutic delivery of gene-silencing agents to pretargeting strategies for imaging and radionuclide therapy, with customized solutions for your specific target and indication.
N-Acetylgalactosamine (GalNAc)
Leverage the power of receptor-mediated delivery with our GalNAc-siRNA conjugation services, the gold standard for hepatocyte-specific RNA therapeutics. Our platform utilizes triantennary GalNAc structures that bind with high affinity to the asialoglycoprotein receptor (ASGPR) abundantly expressed on hepatocytes, enabling specific liver targeting following subcutaneous administration. We incorporate advanced stabilization chemistry including 2'-modifications and phosphorothioate linkages to enhance nuclease resistance and extend therapeutic duration. Our GalNAc conjugates demonstrate excellent safety profiles in toxicology studies, high therapeutic indices, and prolonged duration of action. With multiple GalNAc-siRNA therapeutics advancing through clinical trials for cardiometabolic, rare genetic, and infectious diseases, this platform represents a clinically validated approach for liver-targeted RNA therapeutics. Our services include sequence optimization, chemical modification design, and scalable synthesis for preclinical through clinical development.
Leverage nature's own delivery system with our exosome-based solutions. These nano-sized vesicles (40-120nm) naturally shuttle RNA between cells, offering high stability in circulation, efficient cellular entry, and minimal immunogenicity. Our service includes various exosome origins and targeted delivery options for effective siRNA transfer.
Why Choose Us
- Comprehensive Platform: Access the full spectrum of nucleic acid delivery technologies under one roof, from clinically validated LNPs to innovative bioconjugates and emerging delivery systems.
- Proven Expertise: Leverage our deep experience in formulation science and bioconjugation chemistry, supported by successful delivery of numerous custom projects across diverse therapeutic areas.
- Customized Solutions: Every project receives tailored optimization of formulation parameters, conjugation chemistry, and targeting strategies to meet your specific therapeutic objectives.
- Scalable Technologies: Our platforms support seamless scale-up from research quantities to clinical manufacturing, maintaining quality and reproducibility throughout development.
- Integrated Analytics: Comprehensive characterization services ensure thorough understanding of your formulation's physical, chemical, and biological properties at every stage.
- Regulatory Insight: Benefit from our understanding of regulatory requirements for nucleic acid therapeutics, with documentation and quality systems supporting IND-enabling studies.
